

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Ashkenazi, et al. Docket No.: 39780-1618P2C1-1
Serial No.: 10/797,366 Group Art Unit: 2873
Filing Date: March 9, 2004 Examiner: Unassigned
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND
NUCLEIC ACIDS ENCODING THE SAME**



Office of Initial Patent Examination
Customer Service Center
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the official filing receipt received from the USPTO in the above application for which issuance of a corrected filing receipt is respectfully requested. The domestic priority data and foreign application for this application are incorrectly entered.

The correct priority data, as evidenced by the attached copy of the preliminary amendment filed on March 9, 2004, is:

-- This is a continuation application claiming priority under 35 USC §120 to US serial number 09/665,350 filed 9/18/2000, which is a continuation of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/04414 filed 2/22/2000, and where US serial number 09/665,350 is also a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/23328 filed 8/24/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application

CERTIFICATE OF MAILING (37CFR 1.8 (A))

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Office of Initial Patent Examination, Customer Service Center, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: May 10, 2004

Sandra Puljic
Sandra Puljic

number PCT/US00/20710 filed 7/28/2000, which claims priority under 35 USC §119 to US provisional application number 60/146,222 filed 7/28/1999, and where PCT Application number PCT/US00/20710 is also a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/15264 filed 6/2/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/14042 filed 5/22/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/08439 filed 3/30/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/07377 filed 3/20/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/05841 filed 3/2/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/05004 filed 2/24/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/04414 filed 2/22/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/03565 filed 2/11/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/00219 filed 1/5/2000, which claims priority under 35 USC §119 to US provisional application number 60/145,698 filed 7/26/1999, and where PCT Application number PCT/US00/00219 is also a continuation-in-part of, and claims priority under 35 USC §120 to, both PCT Application numbers: PCT/US99/30999 filed 12/20/1999 and PCT/US99/30911 filed 12/20/1999, which claims priority under 35 USC §119 to US provisional application number 60/143,048 filed 7/7/1999, and where PCT/US99/30999 and PCT/US99/30911 are both continuations-in-part to, and claim priority under 35 USC §120 to, PCT Application number PCT/US99/30095 filed 12/16/1999, which claims priority under 35 USC §119 to US provisional application number 60/113,296 filed 12/22/1998, and where PCT Application number PCT/US99/30095 is also a continuation-in-part of, and claims priority under 35 USC §120 to, both PCT Application numbers: PCT/US99/28565 and PCT/US99/28564 both

filed 12/2/1999, which are also continuations-in-part of, and claim priority under 35 USC §120 to, PCT Application number PCT/US99/28301 filed 12/1/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/28313 filed 11/30/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/28214 filed 11/29/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/23089 filed 10/5/1999, which claims priority under 35 USC §119 to US provisional application number 60/104080 filed 10/13/1998, and where PCT Application number PCT/US99/23089 is also a continuation-in-part of, and claims priority under 35 USC §120 to, both PCT Application numbers: PCT/US99/21547 and PCT/US99/21090 both filed 9/15/1999, which are also continuations-in-part of, and claim priority under 35 USC §120 to, PCT Application number PCT/US99/20944 filed 9/13/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/20594 filed 9/8/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/25108 filed 12/1/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/19437 filed 9/17/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/19330 filed 9/16/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/19177 filed 9/14/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/18824 filed 9/10/1998, which claims priority under 35 USC §119 to US provisional application numbers: 60/059,115 filed 9/17/1997, 60/059,184 filed 9/17/1997, 60/059,122 filed 9/17/1997, 60/059,117 filed 9/17/1997, 60/059,113, filed 9/17/1997, 60/059,121 filed 9/17/1997, 60/059,119 filed 9/17/1997, 60/059,263 filed 9/18/1997, 60/059,266 filed 9/18/1997, 60/062,125 filed 10/15/1997, 60/062,287 filed 10/17/1997, 60/062,285 filed 10/17/1997, 60/063,486 filed 10/21/1997, 60/062,816 filed 10/24/1997, 60/062,814 filed 10/24/1997, 60/063,127 filed 10/24/1997, 60/063,120 filed

10/24/1997, 60/063,121 filed 10/24/1997, 60/063,045 filed 10/24/1997, 60/063,128 filed
10/24/1997, 60/063,329 filed 10/27/1997, 60/063,327 filed 10/27/1997, 60/063,549 filed
10/28/1997, 60/063,541 filed 10/28/1997, 60/063,550 filed 10/28/1997, 60/063,542 filed
10/28/1997, 60/063,544 filed 10/28/1997, 60/063,564 filed 10/28/1997, 60/063,734 filed
10/29/1997, 60/063,738 filed 10/29/1997, 60/063,704 filed 10/29/1997, 60/063,435 filed
10/29/1997, 60/064,215 filed 10/29/1997, 60/063,735 filed 10/29/1997, 60/063,732 filed
10/29/1997, 60/064,103 filed 10/31/1997, 60/063,870 filed 10/31/1997, 60/064,248 filed
11/3/1997, 60/064,809 filed 11/7/1997, 60/065,186 filed 11/12/1997, 60/065,846 filed
11/17/1997, 60/065,693 filed 11/18/1997, 60/066,120 filed 11/21/1997, 60/066,364 filed
11/21/1997, 60/066,772 filed 11/24/1997, 60/066,466 filed 11/24/1997, 60/066,770 filed
11/24/1997, 60/066,511 filed 11/24/1997, 60/066,453 filed 11/24/1997, 60/066,840 filed
11/25/1997, 60/069,425 filed 12/12/1997, 60/088,026 filed 6/4/1998, 60/109,304 filed
11/20/1998, the entire disclosures of which are hereby incorporated by reference.--

The correction is not due to any error by applicant and no fee is due. However, in the event that a fee is due, the Commissioner is hereby authorized to charge any such fees to Deposit Account 08-1641 (Attorney Docket No. 39780-1618P2C1-1).

Respectfully submitted,

Dated: May 10, 2004

Daphne Reddy
Daphne Reddy, Reg. No. 53,507

HELLER EHRMAN WHITE & McAULIFFE LLP

Customer No. 35489/09157

275 Middlefield Road

Menlo Park, CA 94025

Tel: (650) 324-7000

Fax: (650) 324-6638

2032456

Please type a plus sign (+) inside this box ☐


+

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

02-04-05 IFW

Application Number	10/797,366
Filing Date	MARCH 9, 2004
First Named Inventor	AVI ASHKENAZI
Group/Art Unit	2873
Examiner Name	UNASSIGNED
Attorney Docket Number	39780-1618 P2C1-1



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

42

ENCLOSURES (check all that apply)

- | | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input checked="" type="checkbox"/> RESPONSE TO NOTICE REGARDING BENEFIT/PRIORITY CLAIM(S)
<input type="checkbox"/> After Final
<input type="checkbox"/> Version With Markings Showing Changes
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53
<input checked="" type="checkbox"/> COPY OF NOTICE | <input checked="" type="checkbox"/> COPY OF REQUEST FOR CORRECTED FILING RECEIPT
<input checked="" type="checkbox"/> COPY OF PRELIMINARY AMENDMENT OF MARCH 9, 2004
<input checked="" type="checkbox"/> APPLICATION DATA SHEET
<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Request for Refund | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW):
<input checked="" type="checkbox"/> STAMPED RETURN POSTCARD |
|--|--|---|

Remarks

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39780-1618 P2C1-1.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	HELLER EHRMAN WHITE & McAULIFFE LLP	GINGER R. DREGER (Reg. No. 33,055)
	275 Middlefield Road, Menlo Park, California 94025	Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature		
Date	FEBRUARY 2, 2005	Customer Number: 25213

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: **Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450**, on this date: **FEBRUARY 2, 2005**

Express Mail Label EL 993 638 486 US

Typed or printed name	L. ACOSTA		
Signature		Date	FEBRUARY 2, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop ___, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Avi ASHKENAZI, et al.

Application Serial No: 10/797,366

Filed: March 9, 2004

For: **SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

) Attorney Docket No.: 39780-

) 1618P2C1-1

)

) Group Art Unit: 2873

)

)

)

)

)

EXPRESS MAIL LABEL NO. EL 993 638 486 US

Date Mailed: February 2, 2005

RESPONSE TO NOTICE REGARDING BENEFIT/PRIORITY CLAIM(S)

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Dear Sir:

In connection with the above-identified patent application, a Notice Regarding Benefit/Priority Claims(s) was issued on June 4, 2004.

Applicants submit that the Notice was issued in error.

Enclosed herewith are (i) a copy of the Notice; (ii) a copy of Applicants' Request for a Corrected Filing Receipt, including a copy of Applicants' Preliminary Amendment filed March 9, 2004; and (iii) the Application Data Sheet (ADS).

STATEMENT OF FACTS

The present continuation application was filed on March 9, 2004, along with a Preliminary Amendment indicating the domestic and foreign priority data. A copy of said amendment is attached herewith for the PTO's convenience.

On April 22, 2004, the PTO issued the application filing receipt with the wrong priority data listed.

In response, the Applicant filed a "Request for Corrected Filing Receipt" on May 10, 2004. A copy of said Request is attached for the PTO's convenience.

On June 4, 2004, the PTO issued a "Notice Regarding Benefit/Priority Claim(s)". The PTO alleges that a "Prior-Filed Nonprovisional Application has been Improperly Indicated as a National Stage (35 U.S.C. 371) Application." (See page 2 of the instant Notice.) The PTO further alleges that "[a]pplicant submitted a benefit claim to a prior-filed nonprovisional application and improperly indicated that the prior-filed application is a national stage application under 35 U.S.C. 371. The Office's records show that the prior-filed application is an application filed under 35 U.S.C. 111(a)."

Applicants disagree and submit that the Notice was issued in error.

REMARKS

As it is apparent from the attached documents, Applicants' Preliminary Amendment of March 9, 2004 and Request for Corrected Filing Receipt of May 10, 2004 do not contain a claim for priority to a national stage application under 35 U.S.C. 371. Furthermore, the PTO allegation that "[t]he Office's records show that the prior-filed application is an application filed under 35 U.S.C. 111(a)...[t]he Office has entered the benefit claim to the prior-filed application as a benefit claim to an application filed under 35 U.S.C. 111(a)" is erroneous. Accordingly, 35 U.S.C. 111(a)-"Application" provides general guidelines about a new patent application. Accordingly, Section 111(a) is not a proper section to make a claim for priority.

Thus, Applicants believe that the present Notice dated June 4, 2004 was issued in error and ask the PTO to consider and enter the Request for Corrected Filing Receipt filed by the Applicant on May 10, 2004 and the Preliminary Amendment filed on March 9, 2004. For the PTO's convenience, Applicant's enclose herewith an Application Data Sheet (ADS) listing the correct priority information for the present application.

CONCLUSION

For the reasons outlined above, the Applicant respectfully requests the PTO to withdraw the Notice Regarding Benefit/Priority Claim. Additionally, the Applicant requests the PTO to enter the Request for Corrected Filing Receipt dated May 10, 2004 and the preliminary amendment dated March 9, 2004.

Although no fees are believed to be due, the Commissioner is hereby authorized to charge any fees, including any fees for extension of time, or credit overpayment to Deposit Account No. **08-1641** (Attorney's Docket No. **39780-1618P2C1-1**). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully submitted,

Dated: February 2, 2005

By:



Ginger R. Dreger; Reg. No. 33,055

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025

Direct Telephone: (650)-324-7184

Telephone: (650) 324-7000

Facsimile: (650) 324-0638

SV 2098440 v1
2/2/05 1:51 PM (39780.1618)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/797,366	03/09/2004	Avi Ashkenazi	39780-1618P2C1-1

CONFIRMATION NO. 5045

35489

HELLER EHRMAN WHITE & MCAULIFFE LLP **RECEIVED**
275 MIDDLEFIELD ROAD
MENLO PARK, CO 94025-3506



OC000000012875388

JUN 10 2004

HEWM LLP - P.A.

Date Mailed: 06/04/2004



Notice Regarding Benefit/Priority Claim(s)

☐ **Improper Benefit Claim(s) to Prior-Filed Nonprovisional Application(s)**

The benefit claim(s) to prior-filed nonprovisional application(s) is improper because there is no specific reference for each prior-filed application that includes: (1) the identification of the prior-filed application by application number, or international application number and international filing date; and (2) a clear indication the relationship (i.e., continuation, divisional, or continuation-in-part) of the nonprovisional applications. For example, applicant should amend the specification to include a specific reference, such as "This application is a continuation of Application No. 10/---,--- filed ---," in the first sentence of the specification following the title.

Applicant should review each benefit claim submitted and, if appropriate, provide the proper reference to the prior-filed application(s) as required by 37 CFR 1.78. A proper relationship includes an identification of each nonprovisional application as a continuation, divisional or continuation-in-part application of the immediate prior-filed nonprovisional application for which a benefit is claimed under 37 CFR 1.78 in order to establish copendency throughout the entire chain of prior-filed applications. The specific reference must be included in the domestic priority information section of an application data sheet (37 CFR 1.76), or the specification must contain, or be amended to contain, such reference in the first sentence following the title.

Timeliness: The required reference for each benefit claim must be filed during the pendency of the instant application and within the later of: (1) four months from the actual filing date of the instant application, or the national stage commencement date if the instant application is a national stage application under 35 U.S.C. 371; or (2) sixteen months from the filing date of the prior-filed application. Failure to timely file the required reference is considered a waiver of any benefit claim, unless a grantable petition to accept an unintentionally delayed claim under 37 CFR 1.78(a), the surcharge set forth in 37 CFR 1.17(t), and the required reference are filed. See 37 CFR 1.78(a).

☐ **Improper Benefit Claim(s) to Prior-Filed Nonprovisional Application(s)**

The benefit claim(s) to prior-filed provisional application(s) is improper because the instant application was not filed within twelve (12) months from the filing date of the provisional application, and there is no indication of an intermediate nonprovisional application that is directly claiming the

benefit of the provisional application and filed within 12 months of the filing date of the provisional application. For example, applicant should amend the specification to include a specific reference, such as "This application is a continuation of Application No. 10/---,--- filed ---, which claims the benefit of U.S. Provisional Application No. 60/---,--- filed---." in the first sentence of the specification following the title.

Applicant should review each benefit claim submitted and, if appropriate, provide the proper reference to the prior-filed applications (including an indication of any intermediate nonprovisional application that is directly claiming the benefit of the provisional application and filed with 12 months of the filing date of the provisional application) as required by 37 CFR 1.78. The required reference must be included in the domestic priority information section of an application data sheet (37 CFR 1.76), or the specification must contain, or be amended to contain, such reference in the first sentence following the title.

Timeliness: The required reference for each benefit claim must be filed during the pendency of the instant application and within the later of: (1) four months from the actual filing date of the instant application, or the national stage commencement date if the instant application is a national stage application under 35 U.S.C. 371; or (2) sixteen months from the filing date of the prior-filed application. Failure to timely file the required reference is considered a waiver of any benefit claim, unless a grantable petition to accept an unintentionally delayed claim under 37 CFR 1.78(a), the surcharge set forth in 37 CFR 1.17(t), and the required reference are filed during the pendency of the instant application.

☐ **Improper Priority Claim(s) to Prior-Filed Foreign Application(s)**

The instant application was not filed within twelve (12) months from the filing date of the prior-filed foreign application, and there is no benefit claim to an intermediate nonprovisional application filed within 12 months of the filing date of the foreign application. Applicant should review each priority claim submitted and, if appropriate, provide the proper reference to any intermediate nonprovisional application filed within 12 months of the filing date of the foreign application in compliance with 37 CFR 1.78, or delete the priority claim. The required reference to an intermediate nonprovisional application must be included in the domestic priority information section of an application data sheet (37 CFR 1.76), or the specification must contain, or be amended to contain, such reference in the first sentence following the title.

Timeliness: The required reference for the benefit claim to an intermediate nonprovisional application must be filed during the pendency of the instant application and within the later of: (1) four months from the actual filing date of the instant application, or the national stage commencement date if the instant application is a national stage application under 35 U.S.C. 371; or (2) sixteen months from the filing date of the prior-filed application. Failure to timely file the required reference is considered a waiver of any benefit claim, unless a grantable petition to accept an unintentionally delayed claim under 37 CFR 1.78(a), the surcharge set forth in 37 CFR 1.17(t), and the required reference are filed.

☐ **Benefit Claims to More Than 400 Prior-Filed Applications**

The Office's automated system to record and capture benefit claims is only capable of recording benefit claims for 400 prior-filed applications. Therefore, the Office is unable to generate a filing receipt containing benefit claims for more than 400 prior-filed applications even though applicant is entitled to submit benefit claims for more than 400 prior-filed applications. Accordingly, applicant should not request a corrected filing receipt to include benefit claims for more than 400 prior-filed applications.

☒ **Prior-Filed Nonprovisional Application has been Improperly Indicated as a National Stage (35 U.S.C. 371) Application**

Applicant submitted a benefit claim to a prior-filed nonprovisional application and improperly indicated that the prior-filed application is a national stage application under 35 U.S.C. 371. The Office's records show that the prior-filed application is an application filed under 35 U.S.C. 111(a). The Office has entered the benefit claim to the prior-filed application as a benefit claim to an application filed under 35 U.S.C. 111(a). Any request for a corrected filing receipt to include the indication that the prior-filed application is a national stage application will not be granted unless applicant supplies evidence that the prior application was in fact a national stage application. Accordingly, applicant should not submit such request without such evidence. Applicant should submit an amendment (or an application data sheet (ADS) if the benefit claim was submitted in an ADS) to delete the indication that the prior-filed application is a national stage application.

For more information and examples on benefit claims, please see Claiming the Benefit of a Prior-Filed Application under 35 U.S.C. 119(e), 120, 121, and 365(c), 1268 Off. Gaz. Pat. Office 89 (March 18, 2003), which is available on the USPTO website at <http://www.uspto.gov/web/offices/com/sol/og/2003/week11/patbene.htm>, and the Manual of Patent Examining Procedure (MPEP) §§ 201.11 and 201.14.

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Application Data Sheet

Application Information

Application number:: :10/797,366
Filing Date:: March 9, 2004
Application Type:: Regular
Subject Matter:: Utility
Suggested classification::
Suggested Group Art Unit:: 2873
CD-ROM or CD-R?:: None
Number of CD disks::
Number of copies of CDs::
Sequence submission?::
Computer Readable Form (CRF)?::
Number of copies of CRF::
Title:: SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME
Attorney Docket Number:: 39780-1618P2C1-1
Request for Early Publication?:: No
Request for Non-Publication?:: No
Suggested Drawing Figure::
Total Drawing Sheets::
Small Entity?:: No
Latin name::
Variety denomination name::
Petition included?::
Petition Type::
Licensed US Govt. Agency::
Contractor Grant Numbers::

Secrecy Order in Parent Appl.?:

Applicant Information

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Fill Capacity
Given Name:: Avi
Middle Name::
Family Name:: Ashkenazi
Name Suffix::
City of Residence:: San Mateo
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1456 Tarrytown Street
City of mailing address:: San Mateo
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94402

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: David
Middle Name::
Family Name:: Botstein
Name Suffix::
City of Residence:: Belmont
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 2539 Somerset Drive

City of mailing address:: Belmont
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94002

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Luc
Middle Name::
Family Name:: Desnoyers
Name Suffix::

City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 2050 Stockton Street
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94133

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Dan
Middle Name:: L.
Family Name:: Eaton
Name Suffix::
City of Residence:: San Rafael
State or Province of Residence:: CA
Country of Residence:: US

Street of mailing address:: 75 Knight Drive
City of mailing address:: San Rafael
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94901

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Napoleone
Middle Name::
Family Name:: Ferrara
Name Suffix::

City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 2090 Pacific Avenue, #704
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94109

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Ellen
Middle Name::
Family Name:: Filvaroff
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA

Country of Residence:: US
Street of mailing address:: 538 18th Avenue
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94133

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Sherman
Middle Name::
Family Name:: Fong
Name Suffix::
City of Residence:: Alameda
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 19 Basinside Way
City of mailing address:: Alameda
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94502

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Wei-Qiang
Middle Name::
Family Name:: Gao
Name Suffix::
City of Residence:: Palo Alto

State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3025 South Court
City of mailing address:: Palo Alto
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94306

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Switzerland
Status:: Full Capacity
Given Name:: Hanspeter
Middle Name::
Family Name:: Gerber
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1121 Tennessee Street, #5
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94107

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Canada
Status:: Full Capacity
Given Name:: Mary
Middle Name:: E.
Family Name:: Gerritsen
Name Suffix::

City of Residence:: San Mateo
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 541 Parrott Drive
City of mailing address:: San Mateo
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94402

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Canada
Status:: Full Capacity
Given Name:: Audrey
Middle Name::
Family Name:: Goddard
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 110 Congo Street
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94131

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Paul
Middle Name:: J.
Family Name:: Godowski

Name Suffix::
City of Residence:: Hillsborough
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 25 Orange Court
City of mailing address:: Hillsborough
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94010

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Christopher
Middle Name:: J.
Family Name:: Grimaldi
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1434 36th Avenue
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94122

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Austin
Middle Name:: L.

Family Name:: Gurney
Name Suffix::
City of Residence:: Belmont
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1 Debbie Lane
City of mailing address:: Belmont
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94002

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Great Britain
Status:: Full Capacity
Given Name:: Kenneth
Middle Name:: J.
Family Name:: Hillan
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 64 Seward Street
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94114

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Ivar

Middle Name:: J.
Family Name:: Kljavin
Name Suffix::
City of Residence:: Lafayette
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3673 Crescent Drive
City of mailing address:: Lafayette
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94549

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Jennie
Middle Name:: P.
Family Name:: Mather
Name Suffix::
City of Residence:: Millbrae
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 269 La Prenda Drive
City of mailing address:: Millbrae
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94030

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Canada
Status:: Full Capacity

Given Name:: James
Middle Name::
Family Name:: Pan
Name Suffix::
City of Residence:: Belmont
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 2705 Coronet Boulevard
City of mailing address:: Belmont
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94002

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Nicholas
Middle Name:: F.
Family Name:: Paoni
Name Suffix::

City of Residence:: Belmont
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1756 Terrace Drive
City of mailing address:: Belmont
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94002

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US

Status:: Full Capacity
Given Name:: Margaret Ann
Middle Name::
Family Name:: Roy
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 2960 Webster Street #4
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94080

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Timothy
Middle Name:: A.
Family Name:: Stewart
Name Suffix::
City of Residence:: San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 465 Douglass Street
City of mailing address:: San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94114

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Daniel
Middle Name::
Family Name:: Tumas
Name Suffix::
City of Residence:: Orinda
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3 Rae Avenue
City of mailing address:: Orinda
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94563

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: P.
Middle Name:: Mickey
Family Name:: Williams
Name Suffix::
City of Residence:: Half Moon Bay
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 509 Alto Avenue
City of mailing address:: Half Moon Bay
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94019

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	William
Middle Name::	I.
Family Name::	Wood
Name Suffix::	
City of Residence::	Hillsborough
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	35 Southdown Court
City of mailing address::	Hillsborough
State or Province of mailing address::	CA
Country of mailing address::	US
Postal or Zip Code of mailing address::	94010

Correspondence Information

Correspondence Customer Number:: 35489
Name:: HELLER EHRMAN WHITE & McAULIFFE, LLP
Street of mailing address:: 275 Middlefield Road
City of mailing address:: Menlo Park
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94025
Phone number:: (650) 324-7000
Fax Number: (650) 324-0638
E-Mail address:: gdreger@hewm.com

Representative Information

Representative Customer Number::	35489	
----------------------------------	-------	--

- OR -

Representative Designation::	Registration Number::	Representative Name::

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This application	Continuation of	09/665,350	09/18/2000
09/665,350	Continuation of	PCT/US00/04414	02/22/2000
09/665,350	Continuation-in-Part of	PCT/US00/23328	08/24/2000
PCT/US00/23328	Continuation-in-Part of	PCT/US00/20710	07/28/2000
PCT/US00/20710	Claims Priority to	60/146,222	07/28/1999
PCT/US00/20710	Continuation-in-Part of	PCT/US00/15264	06/02/2000
PCT/US00/15264	Continuation-in-Part of	PCT/US00/14042	05/22/2000
PCT/US00/14042	Continuation-in-Part of	PCT/US00/08439	03/30/2000
PCT/US00/08439	Continuation-in-Part of	PCT/US00/07377	03/20/2000
PCT/US00/07377	Continuation-in-Part of	PCT/US00/05841	03/02/2000
PCT/US00/05841	Continuation-in-Part of	PCT/US00/05004	02/24/2000
PCT/US00/05004	Continuation-in-Part of	PCT/US00/04414	02/22/2000
PCT/US00/04414	Continuation-in-Part of	PCT/US00/03565	02/11/2000
PCT/US00/03565	Continuation-in-Part of	PCT/US00/00219	01/05/2000
PCT/US00/00219	Claims Priority to	60/145,698	07/26/1999
PCT/US00/00219	Continuation-in-Part of	PCT/US99/30999 and PCT/US99/30911	12/20/1999 and 12/20/999
PCT/US99/30999 and PCT/US99/30911	Claims Priority to	60/143,048	07/07/1999
PCT/US99/30999 and PCT/US99/30911	Continuation-in-Part of	PCT/US99/30095	12/16/1999
PCT/US99/30095	Claims Priority to	60/113,296	12/22/1998

PCT/US99/30095	Continuation-in-Part of	PCT/US99/28565 and PCT/US99/28564	12/02/1999 and 12/02/1999
PCT/US99/28565 and PCT/US99/28564	Continuation-in-Part of	PCT/US99/28301	12/01/1999
PCT/US99/28301	Continuation-in-Part of	PCT/US99/28313	11/30/1999
PCT/US99/28313	Continuation-in-Part of	PCT/US99/28214	11/29/1999
PCT/US99/28214	Continuation-in-Part of	PCT/US99/23089	10/05/1999
PCT/US99/23089	Claims Priority under	60/104,080	10/13/1998
PCT/US99/23089	Continuation-in-Part of	PCT/US99/21547 and PCT/US99/21090	09/15/1999 and 09/15/1999
PCT/US99/21547 and PCT/US99/21090	Continuation-in-Part of	PCT/US99/20944	09/13/1999
PCT/US99/20944	Continuation-in-Part of	PCT/US99/20594	09/08/1999
PCT/US99/20594	Continuation-in-Part of	PCT/US98/25108	12/01/1998
PCT/US98/25108	Continuation-in-Part of	PCT/US98/19437	09/17/1998
PCT/US98/19437	Continuation-in-Part of	PCT/US98/19330	09/16/1998
PCT/US98/19330	Continuation-in-Part of	PCT/US98/19177	09/14/1998
PCT/US98/19177	Continuation-in-Part of	PCT/US98/18824	09/10/1998
PCT/US98/18824	Claims Priority under	60/059,115	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,184	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,122	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,117	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,113	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,121	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,119	09/17/1997
PCT/US98/18824	Claims Priority under	60/059,263	09/18/1997

PCT/US98/18824	Claims Priority under	60/059,266	09/18/1997
PCT/US98/18824	Claims Priority under	60/062,125	10/15/1997
PCT/US98/18824	Claims Priority under	60/062,287	10/17/1997
PCT/US98/18824	Claims Priority under	60/062,285	10/17/1997
PCT/US98/18824	Claims Priority under	60/063,486	10/21/1997
PCT/US98/18824	Claims Priority under	60/062,816	10/24/1997
PCT/US98/18824	Claims Priority under	60/062,814	10/24/1997
PCT/US98/18824	Claims Priority under	60/063,127	10/24/1997
PCT/US98/18824	Claims Priority under	60/063,120	10/24/1997
PCT/US98/18824	Claims Priority under	60/063,121	10/24/1997
PCT/US98/18824	Claims Priority under	60/063,045	10/24/1997
PCT/US98/18824	Claims Priority under	60/063,128	10/24/1997
PCT/US98/18824	Claims Priority under	60/063,329	10/27/1997
PCT/US98/18824	Claims Priority under	60/063,327	10/27/1997
PCT/US98/18824	Claims Priority under	60/063,549	10/28/1997
PCT/US98/18824	Claims Priority under	60/063,541	10/28/1997
PCT/US98/18824	Claims Priority under	60/063,550	10/28/1997
PCT/US98/18824	Claims Priority under	60/063,542	10/28/1997
PCT/US98/18824	Claims Priority under	60/063,544	10/28/1997
PCT/US98/18824	Claims Priority under	60/063,564	10/28/1997
PCT/US98/18824	Claims Priority under	60/063,734	10/29/1997
PCT/US98/18824	Claims Priority under	60/063,738	10/29/1997
PCT/US98/18824	Claims Priority under	60/063,704	10/29/1997
PCT/US98/18824	Claims Priority under	60/063,435	10/29/1997
PCT/US98/18824	Claims Priority under	60/064,215	10/29/1997
PCT/US98/18824	Claims Priority under	60/063,735	10/29/1997
PCT/US98/18824	Claims Priority under	60/063,732	10/29/1997
PCT/US98/18824	Claims Priority under	60/064,103	10/31/1997
PCT/US98/18824	Claims Priority under	60/063,870	10/31/1997
PCT/US98/18824	Claims Priority under	60/064,248	11/03/1997

PCT/US98/18824	Claims Priority under	60/064,809	11/07/1997
PCT/US98/18824	Claims Priority under	60/065,186	11/12/1997
PCT/US98/18824	Claims Priority under	60/065,846	11/17/1997
PCT/US98/18824	Claims Priority under	60/065,693	11/18/1997
PCT/US98/18824	Claims Priority under	60/066,120	11/21/1997
PCT/US98/18824	Claims Priority under	60/066,364	11/21/1997
PCT/US98/18824	Claims Priority under	60/066,772	11/24/1997
PCT/US98/18824	Claims Priority under	60/066,466	11/24/1997
PCT/US98/18824	Claims Priority under	60/066,770	11/24/1997
PCT/US98/18824	Claims Priority under	60/066,511	11/24/1997
PCT/US98/18824	Claims Priority under	60/066,453	11/24/1997
PCT/US98/18824	Claims Priority under	60/066,840	11/25/1997
PCT/US98/18824	Claims Priority under	60/069,425	12/12/1997
PCT/US98/18824	Claims Priority under	60/088,026	06/04/1998
PCT/US98/18824	Claims Priority under	60/109,304	11/20/1998

Foreign Priority Information

Country::	Application number::	Filing Date::	Priority Claimed::

Assignee Information

Assignee name:: GENENTECH, INC.

Street of mailing address:: 1 DNA WAY

City of mailing address:: South San Francisco

State or Province of mailing address:: CA


Country of mailing address:: US

Postal or Zip Code of mailing address:: 94080

SV 2069052 v1
2/2/05 1:30 PM (39780.1618)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi et al. Docket No.: 39780-1618P2C1-1
Serial No.: Not assigned Group Art Unit: 1646
Filing Date: Herewith Examiner: Kemmerer, Elizabeth
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND
NUCLEIC ACIDS ENCODING THE SAME**



PRELIMINARY AMENDMENT

MS: NO-FEE AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Prior to substantive examination of the above-identified patent application (which is filed concurrently herewith), and prior to calculation of the filing fee, Applicants respectfully request the entry of the following amendments.

CERTIFICATE OF MAILING (37 CFR 1.10(a))

CERTIFICATE OF MAILING BY "EXPRESS MAIL" - Rule 10: I hereby certify that this correspondence is being deposited on March 9, 2004 with the U.S. Postal Service "Express Mail Post Office to Addressee" under 37 CFR 1.10 as Express Mail No. EL993690680US addressed to: Mail Stop: No-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: March 9, 2004


Cheryl Ann Rogers

In the Specification:

Please insert the following paragraph at page 1, line 2:

--RELATED APPLICATIONS

This is a continuation application claiming priority under 35 USC §120 to US serial number 09/665,350 filed 9/18/2000, which is a continuation of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/04414 filed 2/22/2000, and where US serial number 09/665,350 is also a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/23328 filed 8/24/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/20710 filed 7/28/2000, which claims priority under 35 USC §119 to US provisional application number 60/146,222 filed 7/28/1999, and where PCT Application number PCT/US00/20710 is also a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/15264 filed 6/2/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/14042 filed 5/22/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/08439 filed 3/30/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/07377 filed 3/20/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/05841 filed 3/2/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/05004 filed 2/24/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/04414 filed 2/22/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/03565 filed 2/11/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US00/00219 filed 1/5/2000, which claims priority under 35 USC §119 to US provisional application number 60/145,698 filed 7/26/1999, and where PCT Application number PCT/US00/00219 is also a continuation-in-part of, and claims priority under 35 USC §120 to, both PCT Application numbers: PCT/US99/30999 filed 12/20/1999 and PCT/US99/30911 filed 12/20/1999, which claims priority under 35 USC §119 to US provisional application number 60/143,048 filed 7/7/1999, and where PCT/US99/30999 and PCT/US99/30911 are both continuations-in-part to, and claim priority under 35 USC §120 to, PCT Application number

PCT/US99/30095 filed 12/16/1999, which claims priority under 35 USC §119 to US provisional application number 60/113,296 filed 12/22/1998, and where PCT Application number PCT/US99/30095 is also a continuation-in-part of, and claims priority under 35 USC §120 to, both PCT Application numbers: PCT/US99/28565 and PCT/US99/28564 both filed 12/2/1999, which are also continuations-in-part of, and claim priority under 35 USC §120 to, PCT Application number PCT/US99/28301 filed 12/1/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/28313 filed 11/30/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/28214 filed 11/29/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/23089 filed 10/5/1999, which claims priority under 35 USC §119 to US provisional application number 60/104080 filed 10/13/1998, and where PCT Application number PCT/US99/23089 is also a continuation-in-part of, and claims priority under 35 USC §120 to, both PCT Application numbers: PCT/US99/21547 and PCT/US99/21090 both filed 9/15/1999, which are also continuations-in-part of, and claim priority under 35 USC §120 to, PCT Application number PCT/US99/20944 filed 9/13/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US99/20594 filed 9/8/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/25108 filed 12/1/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/19437 filed 9/17/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/19330 filed 9/16/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/19177 filed 9/14/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application number PCT/US98/18824 filed 9/10/1998, which claims priority under 35 USC §119 to US provisional application numbers: 60/059,115 filed 9/17/1997, 60/059,184 filed 9/17/1997, 60/059,122 filed 9/17/1997, 60/059,117 filed 9/17/1997, 60/059,113, filed 9/17/1997, 60/059,121 filed 9/17/1997, 60/059,119 filed 9/17/1997, 60/059,263 filed 9/18/1997, 60/059,266 filed 9/18/1997, 60/062,125 filed 10/15/1997, 60/062,287 filed 10/17/1997, 60/062,285 filed 10/17/1997, 60/063,486 filed 10/21/1997, 60/062,816 filed 10/24/1997, 60/062,814 filed 10/24/1997, 60/063,127 filed 10/24/1997, 60/063,120 filed 10/24/1997, 60/063,121 filed 10/24/1997, 60/063,045 filed

10/24/1997, 60/063,128 filed 10/24/1997, 60/063,329 filed 10/27/1997, 60/063,327 filed 10/27/1997, 60/063,549 filed 10/28/1997, 60/063,541 filed 10/28/1997, 60/063,550 filed 10/28/1997, 60/063,542 filed 10/28/1997, 60/063,544 filed 10/28/1997, 60/063,564 filed 10/28/1997, 60/063,734 filed 10/29/1997, 60/063,738 filed 10/29/1997, 60/063,704 filed 10/29/1997, 60/063,435 filed 10/29/1997, 60/064,215 filed 10/29/1997, 60/063,735 filed 10/29/1997, 60/063,732 filed 10/29/1997, 60/064,103 filed 10/31/1997, 60/063,870 filed 10/31/1997, 60/064,248 filed 11/3/1997, 60/064,809 filed 11/7/1997, 60/065,186 filed 11/12/1997, 60/065,846 filed 11/17/1997, 60/065,693 filed 11/18/1997, 60/066,120 filed 11/21/1997, 60/066,364 filed 11/21/1997, 60/066,772 filed 11/24/1997, 60/066,466 filed 11/24/1997, 60/066,770 filed 11/24/1997, 60/066,511 filed 11/24/1997, 60/066,453 filed 11/24/1997, 60/066,840 filed 11/25/1997, 60/069,425 filed 12/12/1997, 60/088,026 filed 6/4/1998, 60/109,304 filed 11/20/1998, the entire disclosures of which are hereby incorporated by reference.

The paragraph, beginning at page 69, line 6, has been amended as follows:

--Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
~~The NCBI-BLAST2 sequence comparison program may be downloaded from~~
~~http://www.ncbi.nlm.nih.gov.~~ NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.--

The paragraph, beginning at page 71, line 26, has been amended as follows:

--Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
~~The NCBI-BLAST2 sequence comparison program may be downloaded from~~
~~http://www.ncbi.nlm.nih.gov.~~ NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value =

0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.--

The paragraph, beginning at page 147, line 20 has been amended as follows:

--Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, [Rockville, Maryland]Manassas, VA--

The paragraph beginning at page 147, line 27, has been amended as follows:

--The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altschul, and Gish, Methods in Enzymology 266: 460-80 (1996); <http://blast.wustl.edu/blast/README.html>) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a Blast score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington).

The paragraph, beginning at page 154, line 14 has been amended as follows:

--The EST sequence accession number AF007268, a murine fibroblast growth factor (FGF-15) was used to search various public EST databases (e.g., GenBank, Dayhoff, etc.) The search was performed using the computer program BLAST or BLAST2 Altschul et al., Methods in Enzymology, 266:460-480 (1996); <http://blast.wustl.edu/blast/README.html> as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. The search resulted in a hit with GenBank EST AA220994, which has been identified as ~~stratagene~~ Strategene NT2 neuronal precursor 937230.--

The paragraph beginning at page 167, line 30, has been amended as follows:

--The extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases. The EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzymology 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington; <http://bozeman.mbt.washington.edu/phrap-docs/phrap.html>)--.

The paragraph beginning at page 178, line 26, has been amended as follows:

--The extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases. The EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzymology 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington; <http://bozeman.mbt.washington.edu/phrap-docs/phrap.html>)--.

The paragraph, beginning at page 250, line 2, has been amended as follows:

--The following materials have been deposited with the American Type Culture Collection, [12301 Parklawn Drive, Rockville, MD,]10801 University Boulevard, Manassas, VA USA (ATCC):

<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
DNA32292-1131	ATCC 209258	September 16, 1997
DNA33094-1131	ATCC 209256	September 16, 1997
DNA33223-1136	ATCC 209264	September 16, 1997
DNA34435-1140	ATCC 209250	September 16, 1997
DNA27864-1155	ATCC 209375	October 16, 1997
DNA36350-1158	ATCC 209378	October 16, 1997
DNA32290-1164	ATCC 209384	October 16, 1997
DNA35639-1172	ATCC 209396	October 17, 1997
DNA33092-1202	ATCC 209420	October 28, 1997
DNA49435-1219	ATCC 209480	November 21, 1997
DNA35638-1141	ATCC 209265	September 16, 1997
DNA32298-1132	ATCC 209257	September 16, 1997
DNA33089-1132	ATCC 209262	September 16, 1997
DNA33786-1132	ATCC 209253	September 16, 1997
DNA35918-1174	ATCC 209402	October 17, 1997
DNA37150-1178	ATCC 209401	October 17, 1997
DNA38260-1180	ATCC 209397	October 17, 1997
DNA39969-1185	ATCC 209400	October 17, 1997
DNA32286-1191	ATCC 209385	October 16, 1997
DNA33461-1199	ATCC 209367	October 15, 1997
DNA40628-1216	ATCC 209432	November 7, 1997
DNA33221-1133	ATCC 209263	September 16, 1997
DNA33107-1135	ATCC 209251	September 16, 1997
DNA35557-1137	ATCC 209255	September 16, 1997
DNA34434-1139	ATCC 209252	September 16, 1997
DNA33100-1159	ATCC 209373	October 16, 1997
DNA35600-1162	ATCC 209370	October 16, 1997
DNA34436-1238	ATCC 209523	December 10, 1997
DNA33206-1165	ATCC 209372	October 16, 1997
DNA35558-1167	ATCC 209374	October 16, 1997
DNA35599-1168	ATCC 209373	October 16, 1997
DNA36992-1168	ATCC 209382	October 16, 1997
DNA34407-1169	ATCC 209383	October 16, 1997
DNA35841-1173	ATCC 209403	October 17, 1997
DNA33470-1175	ATCC 209398	October 17, 1997
DNA34431-1177	ATCC 209399	October 17, 1997
DNA39510-1181	ATCC 209392	October 17, 1997
DNA39423-1182	ATCC 209387	October 17, 1997
DNA40620-1183	ATCC 209388	October 17, 1997
DNA40604-1187	ATCC 209394	October 17, 1997
DNA38268-1188	ATCC 209421	October 28, 1997
DNA37151-1193	ATCC 209393	October 17, 1997
DNA35673-1201	ATCC 209418	October 28, 1997
DNA40370-1217	ATCC 209485	November 21, 1997
DNA42551-1217	ATCC 209483	November 21, 1997

DNA39520-1217	ATCC 209482	November 21, 1997
DNA41225-1217	ATCC 209491	November 21, 1997
DNA43318-1217	ATCC 209481	November 21, 1997
DNA40587-1231	ATCC 209438	November 7, 1997
DNA41338-1234	ATCC 209927	June 2, 1998
DNA40981-1234	ATCC 209439	November 7, 1997
DNA37140-1234	ATCC 209489	November 21, 1997
DNA40982-1235	ATCC 209433	November 7, 1997
DNA41379-1236	ATCC 209488	November 21, 1997
DNA44167-1243	ATCC 209434	November 7, 1997
DNA39427-1179	ATCC 209395	October 17, 1997
DNA40603-1232	ATCC 209486	November 21, 1997
DNA43466-1225	ATCC 209490	November 21, 1997
DNA43046-1225	ATCC 209484	November 21, 1997
DNA35668-1171	ATCC 209371	October 16, 1997
DNA77624-2515	ATCC 203553	December 22, 1998--

Please replace the paragraph beginning at page 251, line 10, with the following rewritten paragraph:

--These deposit were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations there under (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the pertinent U.S. patent, assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).--

Remarks

The foregoing amendment to the specification deletes all embedded hyperlinks and incorporates the requisite assurances that "all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the pertinent U.S. patent." Applicants respectfully request entry of these amendments for prosecution of this application.

Please charge any additional fees, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No.: 39780-1618P2C1-1).

Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully submitted,

Date: March 9, 2004

Daphne Reddy
Daphne Reddy
Reg. No. 53,507

HELLER EHRMAN WHITE & McAULIFFE LLP

Customer No. 35489

275 Middlefield Road

Menlo Park, California 94025

Telephone: (650) 324-7000

Facsimile: (650) 324-0638

2013282